PDF(Pubmed)
Abstract：
Despite the intramuscular route being the most used vaccination strategy against SARS-CoV-2, the intradermal route has been studied around the globe as a strong candidate for immunization against SARS-CoV-2. Adjuvants have shown to be essential vaccine components that are capable of driving robust immune responses and increasing the vaccination efficacy. In this work, our group aimed to develop a vaccination strategy for SARS-CoV-2 using a trimeric spike protein, by testing the best route with formulations containing the adjuvants AddaS03, CpG, MPL, Alum, or a combination of two of them. Our results showed that formulations that were made with AddaS03 or CpG alone or AddaS03 combined with CpG were able to induce high levels of IgG, IgG1, and IgG2a; high titers of neutralizing antibodies against SARS-CoV-2 original strain; and also induced high hypersensitivity during the challenge with Spike protein and a high level of IFN-γ producing CD4+ T-cells in mice. Altogether, those data indicate that AddaS03, CpG, or both combined may be used as adjuvants in vaccines for COVID-19.
摘要：
尽管肌内途径是针对SARS-CoV-2的最常用的疫苗接种策略，但在全球范围内已研究了皮内途径作为针对SARS-CoV-2的免疫接种的有力候选者。佐剂已被证明是必需的疫苗组分,其能够驱动稳健的免疫应答并增加疫苗接种效力。在这项工作中,我们的小组旨在开发一种使用三聚体刺突蛋白的SARS-CoV-2疫苗接种策略，通过测试含有佐剂AddaS03，CpG的配方的最佳途径，MPL,明矾,或两者的组合。我们的结果表明，用AddaS03或CpG单独或AddaS03与CpG联合制备的制剂能够诱导高水平的IgG，IgG1和IgG2a;针对SARS-CoV-2原始菌株的高滴度的中和抗体;并且在用Spike蛋白和小鼠中高水平的产生IFN-γ的CD4+T细胞的攻击期间也诱导高超敏反应。总之,这些数据表明AddaS03，CpG，或两者联合可用作COVID-19疫苗的佐剂。
